Valirx Plc

Background

Currently, ValiPharma is primarily focused on two drug candidates in both clinical and late stage pre-clinical development for three indications – androgen independent prostate cancer (VAL201), hormone refractory prostate cancer (VAL201) and endometriosis (VAL301).

 

ValiRx is a biotechnology oncology focused company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in “precision” medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.